查看文章

Introduction: Podocan, a novel extracellular matrix glycoprotein, is a smooth muscle cell regulator and abundantly expressed in human atheroma. The association of Podocan with cardiovascular outcome remains unclear. The aim of this study was to assess the predictive value of Podocan concerning adverse outcome in patients admitted with acute chest pain suspected to be acute coronary syndrome (ACS).

Methods: Plasma Podocan was measured with an enzyme immune assay in samples taken upon hospital admission from patients with suspected ACS who were enrolled in the Risk markers in Acute Coronary Syndrome (RACS) study (NCT00521976). RACS was a Norwegian single center study including patients from November 2002 to September 2003. The primary outcome was a composite of all-cause mortality, myocardial infarction, or stroke within 7 years. Additional analyzes included these individual …